Cargando…

CXCR2 modulates bone marrow vascular repair and haematopoietic recovery post‐transplant

Murine models of bone marrow transplantation show that pre‐conditioning regimens affect the integrity of the bone marrow endothelium and that the repair of this vascular niche is an essential pre‐requisite for successful haematopoietic stem and progenitor cell engraftment. Little is known about the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hale, Sarah J. M., Hale, Ashley B. H., Zhang, Youyi, Sweeney, Dominic, Fisher, Nita, van der Garde, Mark, Grabowska, Rita, Pepperell, Emma, Channon, Keith, Martin‐Rendon, Enca, Watt, Suzanne M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Haematological Malignancy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654909/ https://www.ncbi.nlm.nih.gov/pubmed/25757087 http://dx.doi.org/10.1111/bjh.13335

Ejemplares similares

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation
por: Marks, David I, et al.
Publicado: (2011)

Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom
por: Bröckelmann, Paul J., et al.
Publicado: (2018)

Ublituximab (TG‐1101), a novel glycoengineered anti‐CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
por: Sharman, Jeff P., et al.
Publicado: (2016)

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study
por: Jagannath, Sundar, et al.
Publicado: (2018)

Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
por: Dimopoulos, Meletios A., et al.
Publicado: (2017)

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
por: Richardson, Paul G., et al.
Publicado: (2018)

Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome
por: Xu, Jinglan, et al.
Publicado: (2008)

Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma
por: Oflazoglu, Ezogelin, et al.
Publicado: (2008)

Retraction: Fatty acid synthase is a novel therapeutic target in multiple myeloma
por: Okawa, Yutaka, et al.
Publicado: (2008)

Gene expression profiling reveals consistent differences between clinical samples of human leukaemias and their model cell lines
por: Leupin, Nicolas, et al.
Publicado: (2006)

Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma
por: Holtan, Shernan G, et al.
Publicado: (2006)

Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study
por: Pettengell, Ruth, et al.
Publicado: (2008)

An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase
por: Kohlmann, Alexander, et al.
Publicado: (2008)

Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes
por: Gabrilove, Janice, et al.
Publicado: (2008)

Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high ‘life threat’ impact cardiopathy
por: Corazzelli, Gaetano, et al.
Publicado: (2011)

The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research
por: Smith, Alexandra, et al.
Publicado: (2010)

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
por: Chen, Christine, et al.
Publicado: (2009)

Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria
por: Hillmen, Peter, et al.
Publicado: (2013)

Differences in incidence and trends of haematological malignancies in Japan and the United States
por: Chihara, Dai, et al.
Publicado: (2014)

Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
por: Brümmendorf, Tim H., et al.
Publicado: (2015)

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up
por: Ludwig, Heinz, et al.
Publicado: (2015)

CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q)
por: Bello, Erica, et al.
Publicado: (2015)

Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model
por: Gassner, Franz J, et al.
Publicado: (2015)

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity
por: Gandhi, Anita K, et al.
Publicado: (2014)

Wilms’ Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses
por: Uttenthal, Benjamin, et al.
Publicado: (2014)

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN)
por: Gandhi, Anita K, et al.
Publicado: (2014)

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial
por: Brümmendorf, Tim H, et al.
Publicado: (2015)

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
por: Feldman, Tatyana, et al.
Publicado: (2014)

Acute myeloid leukaemia: challenges and real world data from India
por: Philip, Chepsy, et al.
Publicado: (2015)

The long‐term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years
por: Else, Monica, et al.
Publicado: (2015)

A 4‐gene expression score associated with high levels of Wilms Tumor‐1 (WT1) expression is an adverse prognostic factor in acute myeloid leukaemia
por: Niavarani, Ahmadreza, et al.
Publicado: (2016)

An unusual indication for splenectomy in hairy cell leukaemia: a report of three cases with persistent splenomegaly after chemoimmunotherapy
por: Sarid, Nadav, et al.
Publicado: (2015)

Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts
por: Conte, Simona, et al.
Publicado: (2015)

The value of molecular stratification for CEBPA (DM) and NPM1 (MUT) FLT3 (WT) genotypes in older patients with acute myeloid leukaemia
por: Dickson, Glenda J., et al.
Publicado: (2015)

A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma
por: Watanabe, Takashi, et al.
Publicado: (2016)

SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study
por: Nordström, Lena, et al.
Publicado: (2014)

A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
por: Ogura, Michinori, et al.
Publicado: (2014)

Sotatercept in patients with osteolytic lesions of multiple myeloma
por: Abdulkadyrov, Kudrat M, et al.
Publicado: (2014)

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia
por: Stuart, Robert K, et al.
Publicado: (2015)

Systemic Amyloidosis in England: an epidemiological study
por: Pinney, Jennifer H, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_38iph1713l9apf2nk4276ml6kp